| scholarly article | Q13442814 |
| P2093 | author name string | Peter A Zimmerman | |
| Moses J Bockarie | |||
| Rajeev K Mehlotra | |||
| P2860 | cites work | Emergence of FY*A(null) in a Plasmodium vivax-endemic region of Papua New Guinea | Q22010821 |
| Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus | Q28204435 | ||
| Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population | Q28277886 | ||
| Human UGT2B7 catalyzes morphine glucuronidation | Q28302296 | ||
| 3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7) | Q28377165 | ||
| Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance | Q28609383 | ||
| Haplotype reconstruction from genotype data using Imperfect Phylogeny | Q30908816 | ||
| Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria | Q33981416 | ||
| Artemisinin drugs: novel antimalarial agents | Q34075018 | ||
| Oral artesunate dose-response relationship in acute falciparum malaria | Q34113505 | ||
| Artemisinin and its derivatives: an important new class of antimalarial agents | Q34386021 | ||
| Pharmacovigilance of antimalarial treatment in Africa: is it possible? | Q34872414 | ||
| Pharmacogenomics of human UDP-glucuronosyltransferase enzymes | Q35157993 | ||
| Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea | Q35669950 | ||
| Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review. | Q35719078 | ||
| Population pharmacokinetics of artemether and dihydroartemisinin following single intramuscular dosing of artemether in African children with severe falciparum malaria | Q35825927 | ||
| Artemisinin-based combination therapies for uncomplicated malaria | Q36047872 | ||
| Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases | Q36363084 | ||
| Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer | Q36426780 | ||
| Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria | Q36669256 | ||
| Malaria infections are randomly distributed in diverse holoendemic areas of Papua New Guinea | Q37058426 | ||
| Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria | Q37598749 | ||
| UDP-glucuronosyltransferases | Q38234360 | ||
| Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria | Q38906771 | ||
| Phamacokinetics of a single oral dose of dihydroartemisinin in Vietnamese healthy volunteers. | Q39164470 | ||
| Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay | Q39515959 | ||
| Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives | Q39590054 | ||
| A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity | Q40582116 | ||
| The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). | Q41060535 | ||
| Onchocerca volvulus DNA probe classification correlates with epidemiologic patterns of blindness | Q41116441 | ||
| Comparative pharmacokinetics and effect kinetics of orally administered artesunate in healthy volunteers and patients with uncomplicated falciparum malaria | Q43855077 | ||
| Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases | Q44094357 | ||
| Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy | Q44107624 | ||
| Sequence Variability and Candidate Gene Analysis in Two Cancer Patients with Complex Clinical Outcomes During Morphine Therapy | Q44403651 | ||
| Functional Characterization of Human UDP-Glucuronosyltransferase 1A9 Variant, D256N, Found in Japanese Cancer Patients | Q44429351 | ||
| A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine | Q44481071 | ||
| Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism | Q44550578 | ||
| Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxycamptothecin and flavopiridol anticancer drugs | Q44566019 | ||
| The main role of UGT1A9 in the hepatic metabolism of mycophenolic acid and the effects of naturally occurring variants | Q44982057 | ||
| Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. | Q45000626 | ||
| The pharmacokinetics of oral dihydroartemisinin and artesunate in healthy Thai volunteers. | Q45249643 | ||
| Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz | Q46335701 | ||
| The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients | Q46731220 | ||
| Isolation and characterization of the human UGT2B7 gene | Q47856780 | ||
| Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria | Q48026045 | ||
| Zidovudine glucuronidation in human liver: interindividual variability. | Q51000623 | ||
| Disposition and biotransformation of the antiretroviral drug nevirapine in humans. | Q54408488 | ||
| Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver | Q60787038 | ||
| Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y) | Q73632842 | ||
| Three novel single nucleotide polymorphisms in UGT1A9 | Q81197213 | ||
| SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci | Q81459790 | ||
| Substrate specificity of human hepatic udp-glucuronosyltransferases | Q82204314 | ||
| Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects | Q82505479 | ||
| Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients | Q95825715 | ||
| P433 | issue | 1 | |
| P921 | main subject | single-nucleotide polymorphism | Q501128 |
| P304 | page(s) | 1-8 | |
| P577 | publication date | 2006-11-09 | |
| P1433 | published in | European Journal of Clinical Pharmacology | Q1376707 |
| P1476 | title | Prevalence of UGT1A9 and UGT2B7 nonsynonymous single nucleotide polymorphisms in West African, Papua New Guinean, and North American populations | |
| P478 | volume | 63 |
| Q37278622 | Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy |
| Q36024652 | CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment |
| Q62494307 | CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans |
| Q90248911 | CYP2B6*6 Genotype Specific Differences in Artemether-Lumefantrine Disposition in Healthy Volunteers |
| Q35043700 | Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic success |
| Q35295887 | Comparative description of haplotype structure and genetic diversity of MDR1 (ABCB1) in HIV-positive and HIV-negative populations |
| Q33916111 | Expanding the Antimalarial Drug Arsenal-Now, But How? |
| Q38030052 | Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid |
| Q45983432 | Genotype and allele frequencies of polymorphic UGT1A9 in the Polish population. |
| Q55476359 | Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects. |
| Q34020238 | Pharmacogenetics of antimalarial drugs: effect on metabolism and transport |
| Q57395688 | Population-specific documentation of pharmacogenomic markers and their allelic frequencies in FINDbase |
| Q42661955 | Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene |
| Q37620247 | Species and inter-individual differences in metabolic capacity of di(2-ethylhexyl)phthalate (DEHP) between human and mouse livers |
| Q34694931 | The effect of UGTs polymorphism on the auto-induction phase II metabolism-mediated pharmacokinetics of dihydroartemisinin in healthy Chinese subjects after oral administration of a fixed combination of dihydroartemisinin-piperaquine |
| Q37928680 | The pharmacogenetics of antimalaria artemisinin combination therapy |
| Q88171791 | The regioselective glucuronidation of morphine by dimerized human UGT2B7, 1A1, 1A9 and their allelic variants |
| Q30428413 | Tolerance and withdrawal from prolonged opioid use in critically ill children |
| Q33749688 | Treatment with coartem (artemether-lumefantrine) in Papua New Guinea |
| Q30540081 | Variation in human β-defensin genes: new insights from a multi-population study |
| Q36079108 | Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment |
Search more.